NIH Public Access
Author Manuscript
Vaccine. Author manuscript; available in PMC 2015 January 16.
NIH-PA Author Manuscript
Published in final edited form as:
Vaccine. 2014 January 16; 32(4): 507–513. doi:10.1016/j.vaccine.2013.11.022.
Improvement of Antibody Responses by HIV Envelope DNA and
Protein Co-Immunization
Franco Pissani1,2,3,#,¶, Delphine C. Malherbe3,#, Jason T. Schuman4, Harlan Robins5,
Byung S. Park3,6, Shelly J. Krebs2,3,¶, Susan W. Barnett7, and Nancy L. Haigwood1,2,3,*
1Department of Molecular Microbiology and Immunology, Oregon Health & Science University,
Portland OR 97217
2The
Vaccine and Gene Therapy Institute, Beaverton OR 97006
3Oregon
4GE
National Primate Research Center, Beaverton OR 97006
Healthcare, Life Sciences, Piscataway NJ 08854
NIH-PA Author Manuscript
5Division
of Human Biology, Fred Hutchinson Cancer Research Center, Seattle WA 98109
6Department
of Public Health and Preventive Medicine, Oregon Health & Science University,
Portland OR 97239
7Novartis
Institutes for Biomedical Research, Cambridge, MA 02139
Abstract
Background—Developing HIV Envelope (Env) vaccine components that elicit durable and
protective antibody responses is an urgent priority, given the results from the RV144 trial.
Optimization of both the immunogens and vaccination strategies will be needed to generate
potent, durable antibodies. Due to the diversity of HIV, an effective Env-based vaccine will most
likely require an extensive coverage of antigenic variants. A vaccine co-delivering Env
immunogens as DNA and protein components could provide such coverage. Here, we examine a
DNA and protein co-immunization strategy by characterizing the antibody responses and
evaluating the relative contribution of each vaccine component.
NIH-PA Author Manuscript
Method—We co-immunized rabbits with representative subtype A or B HIV gp160 plasmid
DNA plus Env gp140 trimeric glycoprotein and compared the responses to those obtained with
either glycoprotein alone or glycoprotein in combination with empty vector.
Results—DNA and glycoprotein co-immunization was superior to immunization with
glycoprotein alone by enhancing antibody kinetics, magnitude, avidity, and neutralizing potency.
Importantly, the empty DNA vector did not contribute to these responses. Humoral responses
elicited by mismatched DNA and protein components were comparable or higher than the
responses produced by the matched vaccines.
© 2013 Elsevier Ltd. All rights reserved.
*
Corresponding author: Oregon National Primate Research Center, Oregon Health and Science University, 505 NW 185th Avenue,
Beaverton, OR 97006, Phone: (503) 690-5500, Fax: (503) 690-5569, haigwoon@ohsu.edu.
#These authors contributed equally to this work.
¶Current address: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver
Spring, MD 20910
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Pissani et al.
Page 2
NIH-PA Author Manuscript
Conclusion—Our data show that co-delivering DNA and protein can augment antibodies to
Env. The rate and magnitude of immune responses suggest that this approach has the potential to
streamline vaccine regimens by inducing higher antibody responses using fewer vaccinations, an
advantage for a successful HIV vaccine design.
Keywords
HIV; Envelope-based vaccine; DNA+protein co-immunization; neutralizing antibodies
INTRODUCTION
NIH-PA Author Manuscript
The recent report of partial efficacy in the phase III RV144 trial underscores the challenge of
designing HIV vaccines that can protect from infection. Effective vaccines may require
complex regimens to elicit adaptive responses to multiple antigens. In RV144, prime-boost
immunizations with recombinant ALVAC and gp120 proteins, including co-administration
of these components for the last two immunizations, resulted in reduction of viral
acquisition that was associated with antibodies directed to the HIV Envelope protein (Env)
[1, 2]. Neutralizing antibodies (NAbs) can block SIV or SHIV infection in macaques [3–6]
and appear to contribute to the control of post-infection viremia in HIV infected humans [7].
The strength of interactions occurring between polyclonal antibodies and antigen, termed
antibody avidity, has recently emerged as a central feature of antibody-based vaccines [8, 9].
In addition, nonhuman primate (NHP) SIV challenge models have provided additional
evidence that T cell-based vaccines can offer substantial viral control [10] but cannot
prevent infection, in contrast to vaccines that include Env components [11, 12].
NIH-PA Author Manuscript
The vast variability and plasticity of Env are major obstacles to HIV vaccine design, and
vaccines designed to elicit NAbs have resulted in antibodies with relatively narrow breadth
and potency [13–18]. Prime-boost immunizations can increase the conformation dependence
of antibodies [17] with the caveat of prolonged immunization schedules. These results
emphasize the need for vaccines that rapidly elicit potent Env-specific antibodies that
provide better coverage of antigenic variants. There is mounting evidence that indicates
combining Env DNA and protein vaccine components may address this need. Indeed, we
recently demonstrated that co-immunization with HIV-1 envelope DNA and trimeric protein
accelerates the NAb response [19] and elicits T cell responses [20]. These findings have
been extended by other groups who have found similar results of increased humoral
responses in mice and macaques [12] as well as increased NAb breadth [21], but the
contribution of each component has not been addressed yet. Here, in order to further
characterize the env encoded-DNA plus gp140 protein co-immunization strategy, we used
model Env immunogens from two different clades and parsed the contribution of the
individual DNA and protein components by co-immunizing rabbits with either matched or
mismatched subtype A and B immunogens. Our findings demonstrate that regardless of
whether the immunogens were matched or mismatched, co-immunizations with DNA and
protein enhanced the overall antibody response compared to immunizations with protein
alone or empty vector plus protein. Importantly, our results further suggest that combining
Envs derived from different sources may, in some cases, enhance antibody binding, avidity,
and neutralization potency.
MATERIALS AND METHODS
Animals
Female New Zealand White rabbits (Western Oregon Rabbit Company) were housed at
ONPRC; procedures were approved by the OHSU IACUC.
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 3
HIV-1 Env Immunogens and Rabbit Immunizations
NIH-PA Author Manuscript
Codon-optimized SF162 (subtype B) and motif-optimized [22]Q461e2TAIV (subtype A)
gp160 DNA were cloned into pEMC*, and precipitated onto gold bullets to immunize
rabbits intradermally by Gene Gun (Bio-Rad) [19, 23]. Recombinant trimeric gp140 proteins
(50 μg; fully characterized in [13, 24]) mixed with an equal volume of polyethylenimine
adjuvant (PEI, branched; Sigma-Aldrich), were concurrently delivered intramuscularly.
Blood was collected every two weeks and sera were heat-inactivated.
Antibody Assays
Longitudinal binding antibody responses to SF162 and Q461e2TAIV trimeric gp140 were
measured by kinetic ELISA [19] with chimpanzee IgG as standard. The avidity index to
both antigens was determined as described [8] by endpoint ELISA with minor
modifications. Avidity of sera was determined by calculating the midpoint antibody titer
after treatment with 8M Urea compared to PBS for each antigen.
Surface Plasmon Resonance Assays
NIH-PA Author Manuscript
Antibody concentrations were determined on a Biacore T200 (GE Healthcare) at 25°C.
SF162 and Q461e2TAIV trimers were immobilized at 20μg/mL in 10mM acetate buffer
(pH=5.0) to flow cells 2 and 3 on a CM5 chip by amine coupling (8,860RU for SF162and
10,930RU for Q461e2TAIV). 50μg/mL Protein A (Pierce) in 10mM acetate buffer (pH=4.5)
was immobilized on flow cell 4 (2,330RU). The reference flow cell was activated and
blocked with ethanolamine. Samples were diluted into HBS-EP+ buffer with 0.2mg/mL
BSA. An antibody standard containing polyclonal antibodies to both Q461e2TAIV and
SF162 was generated by determining the concentration of a high titer sample (injected at 5
and 100μL/min for 36s) using calibration-free concentration analysis (CFCA). The data
were fit using 8.526 E11 m2/s as a translational diffusion coefficient for IgGs at 25°C.
Experiments were performed at dilutions 1:100 and 1:1600 to determine Env-specific and
total antibody concentrations respectively. This standardized sample was then used to create
a calibration curve to determine the concentration for all other samples, which were tested at
dilutions 1:100 and 1:400. Samples were injected for 3min at 10μL/min. Binding responses
(from a report point 10s after the end of injection) were fit to a calibration curve using the
T200 evaluation software to determine antigen-specific and total IgG concentrations.
Neutralization assay
Serum samples were tested for neutralizing activity in a TZM-bl assay [25] with a pre-bleed
pool as negative control. Data are reported as ID50, 50% inhibitory dilution values.
NIH-PA Author Manuscript
Statistical Analyses
Repeated Measures ANOVA followed by false discovery rate adjustment was used for
longitudinal assays. Area under the curve (AUC) was calculated following the trapezoid rule
after baseline subtraction. The Kruskal-Wallis test was used for comparison among multiple
groups followed by Bonferroni adjustment. For SPR, a Linear Mixed Model, Repeated
Measures ANOVA was followed by Tukey-Kramer adjustment. First order autoregressive
covariance structure was used to account for within subject correlation. Different
comparison adjustment methods and stringent or flexible adjustments were used depending
on the number of comparisons. Analyses were performed with SAS V9.3 (SAS Inc).
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 4
RESULTS
Co-immunization strategy of rabbits with gp160 DNA and gp140 protein
NIH-PA Author Manuscript
Five groups of rabbits (n=4 per group) were immunized four times on weeks 0, 4, 12, and 20
with Env (trimeric gp140) protein either alone or in combination with gp160 env DNA
(Table 1). Of the five, three groups were co-immunized with plasmid DNA encoding gp160
and gp140 Env protein: (i) subtype B DNA plus subtype B protein (Matched B; SF162
[26]); (ii) subtype A DNA plus subtype A protein (Matched A; QA461e2TAIV [27]); (iii)
subtype B DNA plus subtype A protein (Mismatched). As controls, two groups were
immunized with subtype B protein: (iv) empty vector DNA plus subtype B protein (Empty
Vector); and (v) subtype B protein alone (Protein B). At each immunization, rabbits received
50μg of gp140 in PEI adjuvant and 36 μg of DNA delivered by Gene Gun.
Binding antibody responses are similar in Matched and Mismatched vaccine groups
NIH-PA Author Manuscript
We evaluated Env-specific binding antibody responses longitudinally by ELISA against
trimeric subtype A and B antigens. Strong responses were detected in all groups after two
immunizations that were maintained or boosted by subsequent immunizations (Figure 1A).
We observed no difference in responses between the Empty Vector and Protein B groups
(P>0.38), thus showing no adjuvant effect from the vector alone. A similar absence of
adjuvant effect by the vector alone was reported previously in a DNA prime-protein boost
study [28].
Overall binding potency was determined by calculating the Area Under the Curve (AUC)
(Figure 1B). The Matched A and Mismatched groups developed the strongest response
against the subtype A antigen compared to controls (P=0.015 and P=0.05, respectively). As
expected, the Matched A group had higher subtype A binding antibodies than the Protein B
group (P=0.05). Similarly, the Matched B group developed the most potent subtype Bspecific binding antibody response, significantly stronger than the Matched A group
(P=0.004). Subtype A binding responses were indistinguishable between Matched A and
Mismatched groups, both of which received subtype A protein.
DNA+protein co-immunizations enhance avidity
NIH-PA Author Manuscript
We measured antibody avidity to autologous antigens two weeks after immunizations by
comparing the binding titers after treatment with 8M urea or PBS (Figure 2). The
Mismatched and Matched A groups developed the strongest avidity against the autologous
subtype A antigen compared to the Empty Vector group (P=0.0260 and P=0.0569,
respectively) and the Protein B group (P=0.0160 and P=0.0248, respectively). The Matched
B group had a higher avidity towards the autologous B envelope than the Matched A group
(P=0.01). Not surprisingly, these data also show that the co-immunization vaccine strategies
resulted in stronger avidity for their respective cognate subtypes. Both the Empty Vector and
the Protein B groups had a significantly higher avidity to the subtype B antigen than the
Matched A group (P=0.0329 for both). Furthermore, the Matched B group also had a
significantly higher avidity to the subtype B antigen than the Mismatched group that was
immunized with subtype B DNA and subtype A protein (P=0.03). These data suggest that
the protein component is the dominant partner for increasing avidity with this combination
regimen.
Env-specific antibodies are enriched by DNA+protein co-immunizations
To further evaluate the relative contribution of each vaccine component on antibody
production, we used surface plasmon resonance (SPR) to measure the total amount of
subtype A- or B-trimeric gp140-specific antibody responses. Since the binding antibody
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 5
NIH-PA Author Manuscript
titers and avidity were indistinguishable between the Empty Vector and the Protein B
control groups, we used the Protein B group as control for the SPR analysis. Overall, we
found that the antigen-specific responses were nearly identical and significantly higher in
the Mismatched and the Matched B groups compared to the protein only group (P=0.0035
and P=0.003, respectively, Figure 3A).
Consistent with the binding and avidity results, the vaccines with matched subtype
components elicited higher antigen-specific responses by SPR against their cognate antigens
(Figure 3B), and the Mismatched strategy resulted in comparable levels of antigen-specific
responses against both subtype A and B antigens (P=0.6167). For example, the Matched A
group had significantly higher subtype A antigen-specific responses than the Protein B and
the Matched B groups (P=0.0035 and P=0.0421, respectively), and the Matched B group
elicited significantly higher subtype B antigen-specific responses than the Matched A group
(P<0.0001). Interestingly, the Mismatched vaccine elicited significantly stronger subtype A
antigen-specific responses than the Matched B group (P=0.0063) and stronger subtype B
antigen-specific responses than the Matched A group (unadjusted P=0.0392). Finally, we
saw no difference in the responses elicited by the Mismatched vaccine and the Matched A
vaccine against the subtype A antigen (P=0.9981). Taken together, our SPR results show
that protein components drive strong cognate antigen-specific responses and mismatching
could potentially provide an advantage in cross reactivity.
NIH-PA Author Manuscript
Co-immunizations increase the rate of NAb development and their potency
NIH-PA Author Manuscript
We measured neutralization activity against the subtype A and B viruses that were the
source of immunogens in this study. Rabbits co-immunized with Mismatched DNA+Protein
vaccines developed low subtype A NAbs after two immunizations (Figure 4A), and the
Mismatched vaccine regimen resulted in higher subtype A NAbs than the Protein B and the
Empty Vector strategies (P=0.0375 and P=0.0067, respectively). In contrast, rabbits in all
groups developed NAbs against the subtype B virus after two immunizations, and
subsequent co-immunizations greatly potentiated subtype B NAbs in the Matched B and
Mismatched groups. The greater dynamic range observed here with clade B SF162 may be
due to its high sensitivity to neutralization. The Matched B and Mismatched groups had
significantly higher subtype B NAbs than the Matched A group (P=0.0007 for both),
therefore showing that DNA+Protein vaccines elicited higher NAbs against their cognate
antigens. The Matched B and Mismatched groups had significantly higher subtype B NAbs
than the Empty Vector group (P=0.0083 and P=0.0405, respectively) and the Matched B
group also had stronger subtype B NAbs than the Protein B group (P=0.0295) thereby
illustrating the influence of the env DNA component. The Empty Vector and the Protein B
regimens resulted in higher subtype B NAbs than the Matched A group (P=0.0295 and
P=0.0083 respectively), thus showing that the autologous NAb response is mainly driven by
the protein component.
We performed AUC analyses to measure the overall potency of NAbs (Figure 4B). Coimmunization vaccine strategies resulted in significantly greater potency of autologous
NAbs. The Mismatched group developed the strongest NAbs against the subtype A virus
(P=0.034 vs Empty Vector), whereas the Matched B group developed the most potent NAbs
against the subtype B virus (P=0.010 vs Matched A). No differences in subtype A or B
NAbs were detected between the Mismatched and either of the Matched groups.
Effect of DNA+protein co-immunization on neutralization breadth
The model immunogens used in this study have not elicited heterologous NAbs with
previous vaccine regimens [14, 29, 30]. Considering the improvements in avidity and
neutralization potency mediated by the DNA+protein co-immunizations, we tested sera after
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 6
NIH-PA Author Manuscript
the final immunization for neutralization of heterologous viruses (Table 2). Tier 1B, subtype
B viruses BaL.26 and SS1196.1 were modestly neutralized by sera from all rabbits in
Matched B and Mismatched groups. In addition, 75% of rabbits in the Matched B group
neutralized the subtype C virus ZM109F.PB4 at low titers. Matched A Rabbit #1 serum had
low level neutralization of all viruses tested, but the Protein B and Matched A groups had
two non-responders.
DISCUSSION
NIH-PA Author Manuscript
There has been progress in developing HIV and SIV vaccines that can elicit strong T cell
responses [10], but the components and delivery systems to invoke strong B cell responses
are not fully developed [31]. It is therefore critically important to develop immunization
strategies that accelerate the humoral response and enhance avidity. Earlier animal studies
have shown that avidity was inversely correlated with peak post-challenge viremia [9].
Previously, we reported that co-immunizations using gp160-DNA and a recombinant HIVEnv scaffold protein induced NAbs in rabbits and Env-specific CTL in mice. We further
showed that boosting in the setting of DNA priming with DNA+gp140 accelerated NAb
responses in rabbits [19, 20]. Additionally, it was recently shown that DNA+protein
immunization of NHPs conferred neutralization breadth and some protection from SIV
challenge [12, 21]. Comparing the antibody response elicited by co-immunizations with
DNA expressing model gp160 antigens plus trimeric gp140 protein, DNA vector plus
protein or protein alone to determine the relative contribution of each vaccine component is
a novel aspect of the current study. Moreover, we used for the first time a novel calibrationfree concentration analysis (CFCA) method to assess antigen-specific binding antibody
responses in unpurified serum samples. Binding and avidity antibody data showed that the
protein component strongly influences the antibody specificity, and the DNA component
exerts influence in generating autologous NAbs. Mismatching the DNA and protein
components resulted in comparable or higher humoral responses than Matched vaccines.
NIH-PA Author Manuscript
Numerous immunization studies have used Envelope immunogens to elicit NAbs in various
animal models, and, these Envs have induced fairly weak NAbs developing only after
multiple immunizations [8, 13, 17, 18, 29, 30, 32–34]. However, DNA vaccines are distinct
from conventional vaccines because they stimulate both humoral and cellular responses
against antigenic determinants expressed in vivo similar to natural exposure to the pathogen;
despite their low immunogenicity, they act as intrinsic adjuvants [35]. Thus, use of DNA
plasmids in prime-boost regimens is an attractive approach to increase immunogenicity,
although this prolongs immunization schedules. In contrast, our DNA+protein coimmunization strategy accelerated the development of binding and neutralizing antibodies
compared to vaccination with protein only. Similar results were obtained with DNA+protein
co-immunizations in dengue virus and Japanese Encephalitis Virus (JEV) murine vaccine
studies [36, 37]. DNA+protein co-immunizations were also successful at eliciting higher
binding antibody and T cell responses against hepatitis C [38]. In addition, our results reveal
that co-immunization also accelerated the development of HIV Env-specific antibody
avidity, thus showing the advantage of using this approach.
The protein component was the driving factor for elicitation of JE-specific NAbs when
administered as a vaccine mixture with DNA [39] and as a DNA prime–protein boost
vaccine [36]. Our findings also show that the protein component of the vaccine has a
stronger influence on antibody specificity with higher binding and neutralizing antibody
responses against the envelope cognate to the protein component. However, previous studies
also showed that DNA priming improves the magnitude and quality of antibody against
primary HIV-1 isolates as well as the immunogenicity of the specific Env, which is not
accomplished with protein alone [40]. The ability of the DNA component to focus NAbs on
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 7
NIH-PA Author Manuscript
conserved regions [28] and enhance avidity against Env protein vaccines [41] may have
mediated this effect. Similarly we demonstrate here that the DNA component also
contributes to the antibody response, because co-immunizations enhance antibody binding,
antibody avidity, and potency of NAbs, and accelerate the rate of NAb development.
The DNA+protein combinations elicited higher antigen-specific responses towards their
cognate antigens, as demonstrated by binding and neutralizing antibody data, but the
Mismatched group had comparable or at least in one case better responses than the Matched
groups towards their cognate antigens. Indeed, the Mismatched vaccine displayed strong
binding titers against antigens of both subtypes. It also improved subtype A NAbs, as shown
by the Mismatched group having the highest titers of subtype A NAbs, while maintaining
strong subtype B NAbs. Because this study is one using model antigens that principally
target V3 [13, 24]), we did not explore V2 responses, and we can only speculate if the
results that we obtained can be generalized for transmitter/founder Envs or other primary
Envs. Nonetheless, these results are corroborated by a previous DNA prime–protein boost
vaccine study showing that a polyvalent heterologous protein boost elicit a broader NAb
response than a homologous boost [41].
NIH-PA Author Manuscript
In conclusion, our findings show that DNA+protein co-immunization accelerates and
enhances binding and NAb responses and that the DNA empty vector component does not
contribute. Our results also underscore the role of intrinsic Env immunogenicity in inducing
NAb breadth, as despite enhancing the overall antibody response, the effect of DNA+protein
co-immunizations using model antigens on NAb breadth was less impressive. Uncleaved
gp140 trimers have been shown to be less stable and display aberrant conformations
compared to the new cleaved BG505 SOSIP.664 gp140 trimer[42], and thus may also
contribute to this effect. The current study begins to address one obstacle to eliciting potent,
broad NAbs through Env immunizations by shortening the vaccine regimen. We further
highlight the importance of considering intrinsic Env immunogenicity in the selection of
future immunogens. This co-immunization approach has translational potential for HIV
vaccine design when used with newly discovered or engineered Env immunogens.
Acknowledgments
We thank Leonidas Stamatatos and George Sellhorn for the gp140 trimeric proteins used in this study. We are
grateful to Biwei Guo, Shilpi Pandey, Zachary Brower, and Chelsea Smith for technical assistance. We thank Ann
Hessell and Julie Overbaugh for their contribution to the manuscript. We also thank William Sutton for helpful
discussions. TZM-bl and 293T cell lines were obtained from the NIH AIDS Research and Reference Reagent
Program. This work was supported by National Institutes of Health grants P01 AI087064 (H.R. and N.L.H.), P51
OD011092 (N.L.H. and B.P.), and NIH 5 T32 AI7472-17 (F.P.).
NIH-PA Author Manuscript
References
1. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immunecorrelates analysis of an HIV-1 vaccine efficacy trial. The New England journal of medicine. 2012
Apr 5; 366(14):1275–86. [PubMed: 22475592]
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination
with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. The New England journal of
medicine. 2009 Dec 3; 361(23):2209–20. [PubMed: 19843557]
3. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing
monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human
immunodeficiency virus infection. Nature medicine. 2000 Feb; 6(2):200–6.
4. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of
macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive
infusion of neutralizing antibodies. Nat Med. 2000 Feb; 6(2):207–10. [PubMed: 10655111]
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 8
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript
5. Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, Buckler C, et al. Transfer of
neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection:
implications for HIV-1 vaccine development. Proceedings of the National Academy of Sciences of
the United States of America. 2003 Dec 9; 100(25):15131–6. [PubMed: 14627745]
6. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, et al. Neutralizing antibody
directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus
infections of macaque monkeys. Nat Med. 1999 Feb; 5(2):204–10. [PubMed: 9930869]
7. Huang KH, Bonsall D, Katzourakis A, Thomson EC, Fidler SJ, Main J, et al. B-cell depletion
reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun. 2010; 1:102.
[PubMed: 20981030]
8. Sundling C, Forsell MN, O’Dell S, Feng Y, Chakrabarti B, Rao SS, et al. Soluble HIV-1 Env
trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med.
2010 Aug 30; 207(9):2003–17. [PubMed: 20679401]
9. Zhao J, Lai L, Amara RR, Montefiori DC, Villinger F, Chennareddi L, et al. Preclinical studies of
human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env
antibodies and peak postchallenge viremia. Journal of virology. 2009 May; 83(9):4102–11.
[PubMed: 19224993]
10. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early
control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011 May 26;
473(7348):523–7. [PubMed: 21562493]
11. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against
acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012 Feb 2;
482(7383):89–93. [PubMed: 22217938]
12. Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, Alicea C, et al. DNA and virus particle
vaccination protects against acquisition and confers control of viremia upon heterologous simian
immunodeficiency virus challenge. Proceedings of the National Academy of Sciences of the
United States of America. 2013 Feb 19; 110(8):2975–80. [PubMed: 23359688]
13. Blish CA, Sather DN, Sellhorn G, Stamatatos L, Sun Y, Srivastava I, et al. Comparative
immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting
differential exposure of conserved neutralization epitopes. Journal of virology. 2010 Mar; 84(5):
2573–84. [PubMed: 20015987]
14. Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, et al. Antibody responses
elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162derived gp140 envelope immunogens: comparison with those elicited during homologous simian/
human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Journal of
virology. 2006 Sep; 80(17):8745–62. [PubMed: 16912322]
15. Morner A, Douagi I, Forsell MN, Sundling C, Dosenovic P, O’Dell S, et al. Human
immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with
viral vector or stabilized core protein. Journal of virology. 2009 Jan; 83(2):540–51. [PubMed:
19004960]
16. Nabel GJ, Kwong PD, Mascola JR. Progress in the rational design of an AIDS vaccine. Philos
Trans R Soc Lond B Biol Sci. 2011 Oct 12; 366(1579):2759–65. [PubMed: 21893538]
17. Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, Wang S, et al. Two closely related Env
antigens from the same patient elicited different spectra of neutralizing antibodies against
heterologous HIV-1 isolates. J Virol. 2011 May; 85(10):4927–36. [PubMed: 21411542]
18. Zolla-Pazner S, Kong XP, Jiang X, Cardozo T, Nadas A, Cohen S, et al. Cross-clade HIV-1
neutralizing antibodies induced with V3-scaffold protein immunogens following priming with
gp120 DNA. Journal of virology. 2011 Oct; 85(19):9887–98. [PubMed: 21795338]
19. Pissani F, Malherbe DC, Robins H, DeFilippis VR, Park B, Sellhorn G, et al. Motif-optimized
subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when
delivered sequentially. Vaccine. 2012 Aug 10; 30(37):5519–26. [PubMed: 22749601]
20. Jaworski JP, Krebs SJ, Trovato M, Kovarik DN, Brower Z, Sutton WF, et al. Co-immunization
with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing
antibodies and CD8+ T cells. PloS one. 2012; 7(2):e31464. [PubMed: 22359593]
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 9
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript
21. Li J, Valentin A, Kulkarni V, Rosati M, Beach RK, Alicea C, et al. HIV/SIV DNA vaccine
combined with protein in a co-immunization protocol elicits highest humoral responses to
envelope in mice and macaques. Vaccine. 2013 Apr 26.
22. Huang Y, Krasnitz M, Rabadan R, Witten DM, Song Y, Levine AJ, et al. A recoding method to
improve the humoral immune response to an HIV DNA vaccine. PloS one. 2008; 3(9):e3214.
[PubMed: 18791646]
23. Malherbe DC, Doria-Rose NA, Misher L, Beckett T, Puryear WB, Schuman JT, et al. Sequential
immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo
development of neutralizing antibodies. Journal of virology. 2011 Jun; 85(11):5262–74. [PubMed:
21430056]
24. Sellhorn G, Caldwell Z, Mineart C, Stamatatos L. Improving the expression of recombinant
soluble HIV Envelope glycoproteins using pseudo-stable transient transfection. Vaccine. 2009 Dec
11; 28(2):430–6. [PubMed: 19857451]
25. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol
Biol. 2009; 485:395–405. [PubMed: 19020839]
26. Cheng-Mayer C, Brown A, Harouse J, Luciw PA, Mayer AJ. Selection for neutralization resistance
of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence
changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. Journal of
virology. 1999 Jul; 73(7):5294–300. [PubMed: 10364275]
27. Blish CA, Nguyen MA, Overbaugh J. Enhancing exposure of HIV-1 neutralization epitopes
through mutations in gp41. PLoS medicine. 2008 Jan 3.5(1):e9. [PubMed: 18177204]
28. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, et al. Improved induction of
antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA
prime-protein boost vaccination compared to gp120 protein-only vaccination. Journal of virology.
2008 Aug; 82(15):7369–78. [PubMed: 18495775]
29. Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, Hilt S, et al. Purification, characterization,
and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2
loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. Journal of
virology. 2003 Oct; 77(20):11244–59. [PubMed: 14512572]
30. Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, et al. Correlation of
vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute
viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus
macaques. Journal of virology. 2009 Jan; 83(2):791–801. [PubMed: 18971271]
31. Hoxie JA. Toward an antibody-based HIV-1 vaccine. Annual review of medicine. 2010; 61:135–
52.
32. Sundling C, O’Dell S, Douagi I, Forsell MN, Morner A, Lore K, et al. Immunization with wildtype or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following
heterologous challenge with simian-human immunodeficiency virus. Journal of virology. 2010
Sep; 84(18):9086–95. [PubMed: 20610729]
33. Nkolola JP, Peng H, Settembre EC, Freeman M, Grandpre LE, Devoy C, et al. Breadth of
neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140
envelope trimers in guinea pigs. J Virol. 2010 Apr; 84(7):3270–9. [PubMed: 20053749]
34. Dupuy LC, Locher CP, Paidhungat M, Richards MJ, Lind CM, Bakken R, et al. Directed molecular
evolution improves the immunogenicity and protective efficacy of a Venezuelan equine
encephalitis virus DNA vaccine. Vaccine. 2009 Jun 24; 27(31):4152–60. [PubMed: 19406186]
35. Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T, Akira S, et al. Novel strategies to improve
DNA vaccine immunogenicity. Current gene therapy. 2011 Dec; 11(6):479–84. [PubMed:
22023477]
36. Konishi E, Terazawa A, Imoto J. Simultaneous immunization with DNA and protein vaccines
against Japanese encephalitis or dengue synergistically increases their own abilities to induce
neutralizing antibody in mice. Vaccine. 2003 May 16; 21(17–18):1826–32. [PubMed: 12706666]
37. Simmons M, Murphy GS, Kochel T, Raviprakash K, Hayes CG. Characterization of antibody
responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am J
Trop Med Hyg. 2001 Nov; 65(5):420–6. [PubMed: 11716093]
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 10
NIH-PA Author Manuscript
38. Masalova OV, Lesnova EI, Pichugin AV, Melnikova TM, Grabovetsky VV, Petrakova NV, et al.
The successful immune response against hepatitis C nonstructural protein 5A (NS5A) requires
heterologous DNA/protein immunization. Vaccine. 2010 Feb 23; 28(8):1987–96. [PubMed:
20188254]
39. Imoto J, Konishi E. Needle-free jet injection of a mixture of Japanese encephalitis DNA and
protein vaccines: a strategy to effectively enhance immunogenicity of the DNA vaccine in a
murine model. Viral immunology. 2005; 18(1):205–12. [PubMed: 15802965]
40. Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, et al. Enhanced
immunogenicity of gp120 protein when combined with recombinant DNA priming to generate
antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.
Journal of virology. 2005 Jun; 79(12):7933–7. [PubMed: 15919951]
41. Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or
heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.
Vaccine. 2010 Apr 9; 28(17):2999–3007. [PubMed: 20170767]
42. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, et al. A Next-Generation
Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for
Broadly Neutralizing but Not Non-Neutralizing Antibodies. PLoS pathogens. 2013 Sep.
9(9):e1003618. [PubMed: 24068931]
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 11
Highlights for Review
NIH-PA Author Manuscript
We co-immunized rabbits with clade A or B HIV gp160 plasmid DNA plus Env
gp140 trimer
DNA+Protein co-immunization was superior to immunization with protein alone
Co-immunization enhanced antibody kinetics, magnitude, avidity, neutralizing
potency
The protein component drove the antibody avidity and neutralizing responses
Mismatched vaccines elicited comparable/better humoral responses than matched
ones
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 12
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Figure 1. Autologous Envelope-binding antibody response
NIH-PA Author Manuscript
(A) Longitudinal analysis of binding antibody titers measured by kinetic ELISA against
autologous (vaccine) subtype A (Q461e2TAIV, left) and B (SF162, right) trimeric gp140.
Arrows indicate co-immunization timepoints. (B) Area Under the Curve analysis of
longitudinal binding curves, expressed as relative units. Each symbol represents an
individual rabbit. P values are indicated (Kruskal-Wallis test followed by Bonferroni
adjustment).
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 13
NIH-PA Author Manuscript
Figure 2. Potency of antibody avidity to autologous Envs
NIH-PA Author Manuscript
Avidity indices were determined by 8M urea displacement ELISA two weeks after
immunization against subtype A (Q461e2TAIV, left) and B (SF162, right) vaccine gp140
Envs. P values were determined by Repeated Measures ANOVA followed by false
discovery rate adjustment. For autologous subtype A avidity indices: Mismatched vs Empty
Vector, P=0.0260; Matched A vs Empty Vector, P=0.0569; Matched A vs Protein B,
P=0.0248 and Mismatched vs Protein B, P=0.0160. For autologous subtype B avidity
indices: Matched B vs Matched A, P=0.01; Matched B vs Mismatched, P=0.03; Empty
Vector vs Matched A, P=0.0329 and Protein B vs Matched A, P=0.0329.
NIH-PA Author Manuscript
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 14
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Figure 3. Subtype A and B autologous Envelope-specific antibodies
Subtype A (Q461e2TAIV) and B (SF162) Envelope-specific antibodies present in rabbit
antisera two weeks after immunization were assessed by surface plasmon resonance and
reported as percent of total IgG. (A) Total Subtype A and B Envelope-specific IgG
responses in each vaccine group. (B) Subtype-specific Envelope IgG response (Subtype A
Q461e2TAIV, closed bars; Subtype B SF162, open bars) within each vaccine group. P
values are indicated (Linear Mixed Model Repeated Measures ANOVA with Tukey-Kramer
adjustment).
Vaccine. Author manuscript; available in PMC 2015 January 16.
Pissani et al.
Page 15
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Figure 4. Neutralization potency against vaccine antigens
Rabbit antisera were tested for neutralization of autologous subtype A (Q461e2TAIV, left
panels) and B (SF162, right panels) viruses by TZM-bl neutralization assay. (A) 50%
neutralization (ID50) of rabbit immune sera displayed longitudinally. Arrows indicate coimmunization timepoints. P values were determined by Repeated Measures ANOVA
followed by false discovery rate adjustment. For autologous subtype A NAbs: Mismatched
vs Protein B, P=0.0375; Mismatched vs Empty Vector, P=0.0067. For autologous subtype B
NAbs: Matched B vs Matched A, P=0.0007; Mismatched vs Matched A, P=0.0007;
Matched B vs Empty Vector, P=0.0083; Mismatched vs Empty Vector, P=0.0405; Matched
B vs Protein B, P=0.0295; Empty Vector vs Matched A, P=0.0295 and Protein B vs
Matched A, P=0.0083. (B) Area Under the Curve analysis of longitudinal neutralization
data, expressed as relative units. Each symbol represents an individual rabbit. P values are
indicated (Kruskal-Wallis test followed by Bonferroni adjustment).
NIH-PA Author Manuscript
Vaccine. Author manuscript; available in PMC 2015 January 16.
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Table 1
Vaccine. Author manuscript; available in PMC 2015 January 16.
Vaccine
DNA component
Protein component
Protein B
None
Subtype B (SF162)
Empty Vector/Protein B
pEMC*
Subtype B (SF162)
Matched B
Subtype B (SF162)
Subtype B (SF162)
Mismatched
Subtype B (SF162)
Subtype A (Q461e2TAIV)
Matched A
Subtype A (Q461e2TAIV)
Subtype A (Q461e2TAIV)
Pissani et al.
Co-immunization strategies
Five groups of rabbits (n=4) were co-immunized with different combinations of gp160 envelope DNA (36 μg via Gene gun, intradermal) and gp140 trimeric protein (50 μg, intramuscular) in presence of
PEI adjuvant. Rabbits were vaccinated at weeks 0, 4, 12 and 20.
Page 16
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Table 2
Viral isolates
BaL.26 (B)
SS1196.1 (B)
JRCSE (B)
YU-2 (B)
QH0692 (B)
TRO.11 (B)
ZM109F.PB4 (C)
Pissani et al.
Heterologous neutralization activity of rabbit immune sera
10
Protein B
Vaccine. Author manuscript; available in PMC 2015 January 16.
27
15
23
14
27
15
71
57
31
30
30
17
34
37
21
49
73
20
25
21
11
24
41
58
78
19
22
13
Matched B
Vaccine groups
18
Mismatched
Matched A
62
49
59
42
141
19
Serum ID50
<10
10–20
21–50
51–100
>100
Page 17